Try our Advanced Search for more refined results

BURLINGTON DRUG CO., INC. et al v. PFIZER INC. et al

  1. August 28, 2024

    Lipitor Buyers Seek Final OK For $35M Deal In Antitrust Fight

    End-payor plaintiffs asked a New Jersey federal judge Tuesday to give final approval of a $35 million settlement resolving their antitrust claims against Pfizer over the cholesterol medication Lipitor.

  2. June 12, 2024

    Lipitor Buyers Get Final OK For $93M Deal In Antitrust Fight

    A New Jersey federal judge gave final approval Wednesday to a $93 million settlement between a class of buyers of Lipitor and Pfizer, resolving their claims in sprawling antitrust litigation that Pfizer conspired with a drug manufacturer to delay the release of a cheaper generic version of Lipitor and monopolize the market.

  3. June 07, 2024

    Ranbaxy Units Overcome Lipitor Antitrust MDL

    Multiple Ranbaxy Inc. entities have defeated multidistrict litigation accusing them of conspiring with Pfizer Inc. to delay releasing a generic alternative to blood pressure drug Lipitor, as a New Jersey federal judge on Thursday criticized the drug purchasers' "speculative" arguments.

  4. May 21, 2024

    $93M Lipitor Antitrust Deal Sparks Dispute Over Fee Division

    Attorneys representing a class of buyers in antitrust litigation against Pfizer over the cholesterol medication Lipitor are squabbling over how to divide up to $31 million in attorney fees before a New Jersey federal judge even approves the total, according to court documents.

  5. April 25, 2024

    Class Counsel Seeks $31M From $93M Lipitor Settlement

    Attorneys representing a class of buyers in antitrust litigation against Pfizer over the cholesterol medication Lipitor have asked a New Jersey federal judge to approve their request for $31 million in fees after the two sides agreed to a $93 million settlement in February.

  6. February 14, 2024

    Pfizer Reaches $93M Deal With Lipitor Buyers In Antitrust MDL

    Pfizer Inc. has agreed to shell out $93 million to put to rest Lipitor buyers' claims in sprawling antitrust multidistrict litigation over the cholesterol medication that stretches back more than a decade, according to a motion filed Wednesday in New Jersey federal court.

  7. October 10, 2023

    Lipitor Hearing Punted As Ranbaxy Counsel 'Trapped' In Israel

    A New Jersey federal judge on Tuesday agreed to postpone class certification hearings in antitrust multidistrict litigation over cholesterol medication Lipitor after Ranbaxy Laboratories Ltd. told the court an unidentified attorney is "currently trapped in the war zone in Israel with no foreseeable way to get out."

  8. December 06, 2022

    Lipitor Buyers Say Calif. Group Can't Move Claims Out Of NJ

    A group of consumers who allegedly overpaid for cholesterol medication Lipitor are pushing back against a faction of California consumers' attempts to transfer their claims from New Jersey to the Golden State, claiming that the remand would be detrimental to the multidistrict litigation.

  9. October 07, 2020

    Calif. Consumers Want 2nd Shot At Lipitor Antitrust Subclass

    Two California women asked a New Jersey court Tuesday to reconsider its ruling that they can't create a subclass of Golden State consumers in antitrust litigation against Pfizer Inc. and Ranbaxy Inc. over the cholesterol drug Lipitor, arguing that the judge's ruling last month was an error.

  10. September 22, 2020

    California Consumers Lose Bid For Subclass In Lipitor Case

    A New Jersey federal judge on Tuesday shot down a bid from two California women to create a subclass of Golden State consumers in antitrust litigation against Pfizer Inc. and Ranbaxy Inc. over the cholesterol drug Lipitor, swatting away claims of a purported conflict of interest between them and other end-payors.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!